Maine's PBM Disclosure Law Upheld by Federal Courts
A federal court has given a thumbsupto a controversial Maine law requiringpharmacy benefit managers (PBMs)in that state to report payments fromdrug manufacturers seeking to gainpreference for their products, and to discloseconflicts of interest in establishingformularies. The court's ruling, whichheld that Maine's Unfair PrescriptionDrug Practices Act does not infringe onfederal pension law or violate the civilrights of PBMs, increases the prospectsfor passage of similar disclosure laws ina number of other states.
The National Community PharmacistsAssociation (NCPA), which hasbeen advocating enactment of suchPBM regulations by state legislatures,hailed the decision upholding theMaine law as a positive developmentfor pharmacists and consumers. "Forfar too long, PBMs have been permittedto operate behind a veil of secrecy-without any regulation-puttingpatients and payers at a great disadvantage,"said NCPA Executive VicePresident Bruce Roberts. "We hope thatMaine's law, and the ruling thatupholds it, will serve as an example forthe rest of the nation."
The ruling upheld by the federaljudge concluded that the PBM industryintroduce a "layer of fog to the marketthat prevents benefits managers fromfully understanding how best to minimizetheir net prescription drug costs."
Mr. Rankin is a freelance medical writer.
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025